Taken together, these results indicate that CDK1 physically binds to ACSL4 and increases the K48‐linked polyubiquitination of ACSL4 in a UBR5‐dependent manner, leading to ACSL4 protein degradation in oxaliplatin‐resistant CRC cells. Here, CDK1 is linked to colorectal carcinoma.